These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9216832)

  • 1. Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.
    Negash K; Nichols DE; Watts VJ; Mailman RB
    J Med Chem; 1997 Jul; 40(14):2140-7. PubMed ID: 9216832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
    Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
    J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
    Mottola DM; Laiter S; Watts VJ; Tropsha A; Wyrick SD; Nichols DE; Mailman RB
    J Med Chem; 1996 Jan; 39(1):285-96. PubMed ID: 8568818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
    Cueva JP; Giorgioni G; Grubbs RA; Chemel BR; Watts VJ; Nichols DE
    J Med Chem; 2006 Nov; 49(23):6848-57. PubMed ID: 17154515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms.
    Grubbs RA; Lewis MM; Owens-Vance C; Gay EA; Jassen AK; Mailman RB; Nichols DE
    Bioorg Med Chem; 2004 Mar; 12(6):1403-12. PubMed ID: 15018913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane.
    Doll MK; Nichols DE; Kilts JD; Prioleau C; Lawler CP; Lewis MM; Mailman RB
    J Med Chem; 1999 Mar; 42(5):935-40. PubMed ID: 10072690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.
    Cueva JP; Chemel BR; Juncosa JI; Lill MA; Watts VJ; Nichols DE
    Eur J Med Chem; 2012 Feb; 48():97-107. PubMed ID: 22204903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.
    Brewster WK; Nichols DE; Watts VJ; Riggs RM; Mottola D; Mailman RB
    J Med Chem; 1995 Jan; 38(2):318-27. PubMed ID: 7830274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine.
    Snyder SE; Aviles-Garay FA; Chakraborti R; Nichols DE; Watts VJ; Mailman RB
    J Med Chem; 1995 Jun; 38(13):2395-409. PubMed ID: 7608904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding and preliminary evaluation of 5-hydroxy- and 10-hydroxy-2,3, 12,12a-tetrahydro-1H-[1]benzoxepino[2,3,4-ij]isoquinolines as dopamine receptor ligands.
    Claudi F; Di Stefano A; Napolitani F; Cingolani GM; Giorgioni G; Fontenla JA; Montenegro GY; Rivas ME; Rosa E; Michelotto B; Orlando G; Brunetti L
    J Med Chem; 2000 Feb; 43(4):599-608. PubMed ID: 10691686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
    Jutkiewicz EM; Bergman J
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
    Ralph RJ; Caine SB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
    Knoerzer TA; Watts VJ; Nichols DE; Mailman RB
    J Med Chem; 1995 Aug; 38(16):3062-70. PubMed ID: 7636869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
    Brusniak MY; Pearlman RS; Neve KA; Wilcox RE
    J Med Chem; 1996 Feb; 39(4):850-9. PubMed ID: 8632409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D1 receptor ligands: where are we now and where are we going.
    Zhang J; Xiong B; Zhen X; Zhang A
    Med Res Rev; 2009 Mar; 29(2):272-94. PubMed ID: 18642350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group.
    Seiler MP; Hagenbach A; Wüthrich HJ; Markstein R
    J Med Chem; 1991 Jan; 34(1):303-7. PubMed ID: 1671417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats.
    Shuto T; Seeman P; Kuroiwa M; Nishi A
    Eur J Neurosci; 2008 May; 27(10):2551-7. PubMed ID: 18489579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.
    Gu YG; Bayburt EK; Michaelides MR; Lin CW; Shiosaki K
    Bioorg Med Chem Lett; 1999 May; 9(10):1341-6. PubMed ID: 10360732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.